Cambridge, MA-based biotech giant Genzyme (NASDAQ: [[ticker:GENZ]]) has forged a research agreement with French startup Fovea Pharmaceuticals. The deal—financial terms of which were not disclosed—is aimed a developing gene-based therapies for preventing or ameliorating blindness.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
